Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 15Paraganglioma 4Meningioma 4Carcinoma, Neuroendocrine 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoid Tumor 2Somatostatinoma 1Serotonin Syndrome 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Neuroblastoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Disease Progression 1Carcinoma, Merkel Cell 1Carcinoid Heart Disease 1Breast Neoplasms 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

pasireotide 4Temozolomide 2lutetium Lu 177 dotatate 1farletuzumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tranexamic Acid 1Thyrotropin-Releasing Hormone 1TBR-760 1Rosiglitazone 1Nivolumab 1Microarray Analysis 1Lapatinib 1Ipilimumab 1DNA Methylation 1Complementary Therapies 1Capecitabine 1Cabergoline 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pituitary Neoplasms × lutetium Lu 177 dotatate × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡